Artrya secures UK, EU approvals for Salix
Within a week, ASX-listed medtech company Artrya received both regulatory approvals from the European Union and the United Kingdom for its Salix Coronary Anatomy product.
The AI-powered software identifies and analyses arterial plaque to diagnose coronary artery disease.
The recent certifications allow Artrya to market Salix in 28 EU member countries and...
Medical technology firm Artrya has been cleared by the Australian government to commercialise an AI tool that diagnoses coronary heart disease. It has partnered with Perth-based radiology practice Envision Medical Imaging to market the product by early next year.
WHAT IT'S ABOUT
The AI tool,Salix, has been developed through the collaboration of researchers from the University of Western Australia...
Heart attack patients at the Royal Free Hospital in London are to benefit from a new artificial intelligence (AI) backed keyhole procedure.
Abbott Ultreon 1.0 software merges optical coherence tomography (OCT), an imaging tool that provides cardiologists a view inside an artery or blood vessel, with AI technology for enhanced visualisation.
This combined technology can detect the severity of...
HeartFlow, a company that specializes in creating computerized heart models to treat coronary diseases, announced that its HeartFlow fractional flow reserved from CT (FFRct) Analysis will be covered under UnitedHealthcare's plan.
The deal would put the the Redwood City, California-based company’s tech within reach of an additional 45 million beneficiaries, according to a statement, bringing...
Researchers at the Mayo Clinic believe that there may be a relationship between voice characteristics and heart disease, meaning that doctors might someday use voice-analyzing software as a non-invasive, complementary diagnostic tool.
Today, the Mayo Clinic released results of a study carried out with Beyond Verbal, an Israel-based voice analytics company, that used a smartphone app to measure...
